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Male, Female, Other: Transgender and the impact in primary care 
 
Abstract 
Transgender includes patients at various stages of their journey. It is important that 
providers care for transgender patients with a culturally sensitive approach, awareness, and 
competent skill. There are new terms to learn.  There may be mental health issues and/or 
substance use issues. Hormone therapy can have an impact on a person’s health.  As a primary 
care provider, it is important to be alert to these potential issues, addressing the patient’s 
individual needs. This paper discusses the transgender patient, outlining basic care and issues 
that can arise in a primary care setting. 
Keywords: transgender; hormone therapy; primary care 
Background 
Incidence 
Transgender individuals come from a variety of backgrounds, races, religions, ethnic 
groups, and socioeconomic statuses, with many having fully productive lives. The incidence of 
transgender persons is difficult to estimate due to lack of uniform data collection, with a wide 
range of estimates for both transfemale/male-to-female (MTF) and transmale/female-to-male 
(FTM) (Roberts and Fantz, 2014). The incidence is most likely to be much higher as data does 
not capture individuals who do not have a primary provider or may be obtaining their treatments 
from unauthorized individuals. With the passing of the Affordable Care Act came provisions for 
stronger data collection so it is hoped that more accurate data will be available in the near future. 
Disparities 
Transgender individuals face health disparities related to social stigma, discrimination, 
and denial of human rights. This results in higher rates of HIV/STDs, victimization, substance 
abuse, and psychiatric disorders (U.S. Department of Health and Human Services, 2015). 
Transgender youth are more likely to be homeless and two to three times more likely to attempt 
suicide (U.S. Dept. of Health and Human Services, 2015). Elderly transgender individuals have 
additional barriers to healthcare due to isolation and lack of trained social services and providers. 
Transgender people are also less likely to have health insurance (U.S. Dept. of Health and 
Human Services, 2015). 
Barriers to healthcare for the transgender person tend to center around four main issues: 
the reluctance to disclose one’s identity, the lack of experienced providers and resources, 
financial barriers, and structural barriers (Roberts and Fantz, 2014). Disclosure can range from 
the difficulty communicating with the primary provider as well as others in the community, such 
as pharmacist or laboratory technician (Redfern and Sinclair, 2014). Structural barriers include 
lack of unisex restrooms, inpatient room assignment based on gender, accurate documentation in 
electronic record and billing/coding systems, and appropriate reference ranges in laboratory 
systems. Financial barriers include lack of insurance coverage for gender specific laboratory 
testing, medications, and reassignment surgery. Some people have benefit limits of mental health 
visits per year. Medical and nursing programs lack education related to the care of the 
transgender patient, making the availability of quality, culturally competent care sparse. One of 
the goals of Healthy People 2020 (2010) is to improve the health, safety, and wellbeing of 
transgender individuals by providing culturally competent health care and improving education 
of transgender patients in medical schools. (U.S. Department of Health and Human Services, 
2015). This should include education and awareness by all health care providers, increasing the 
number of providers capable of delivering competent care, and thus improving access to care. 
Resources for the provider are included in table 1.  
Considerations in Primary Care 
Transgender defined 
Gender dysphoria is recognized by the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5) as a mental health condition. (American Psychiatric Association, 2013). 
There is new terminology specific to the transgender population (Gay Alliance, 2013; Alegria, 
2011). Gender is often mistakenly referred to when identifying whether someone was born a 
female or a male, a very distinct binary concept. What many people believe as gender is actually 
sex, which is the biological assignment at birth, the physical attributes of a person. It is important 
for the practitioner to not interchange these terms as they hold different meaning to different 
individuals. Characteristics of Gender dysphoria, along with other terminology are described in 
table 2. 
Cultural Competency 
As a provider, awareness of a person’s gender identity and biological sex is essential in 
order to provide competent care and recommend appropriate care and measures for conditions 
specific to this population (Holmes and Freeman, 2012). It is important for the provider to 
address the patient with their preferred name and not document in their record with their 
preferred name in quotation marks. The provider needs to understand the patient and desired 
goals in order to provide patient-centered quality care and improved outcomes. Key elements of 
culturally competent care include the following: being respectful--if you are not sure how 
someone identifies, then it is proper to ask in a respectful way and in a private place; do not 
assume that sex reassignment surgery is the goal for all transgender people; remember that 
gender identity does not define sexual orientation; maintain privacy of all patients; and use 
preferred name when referring to the past (Gay Alliance, n.d.).    
Role of the NP 
 Nurse practitioners are essential components to the care of the transgender patient. Roles 
include care coordination, creation of the shared care plan, and provision of primary care as well 
as specialty care, depending upon the training and level of expertise of the practitioner. There is a 
process, preferably called a “transition” that transgender individuals become involved with in 
regards to their sexual identity. It is a very individualized process that is dictated by that person’s 
choices. It may include hormone replacement therapy, counseling, and surgery. This process is to 
facilitate congruency between the person’s internal and external expression. Hormonal therapy 
aids in the physical expression of the desired gender. The counseling addresses the mental health 
issues. The individual learns to cope with the stress that they encounter, both internally and 
externally, in regards to their chosen gender identity. Surgery addresses the permanent physical 
change that some individuals seek in order to live more congruently with their chosen gender 
identity. Transmale patients may elect to undergo breast reduction or bilateral mastectomy, often 
referred to as “top surgery”.  They may also elect for a hysterectomy, salpingo-oophorectomy, 
and phalloplasty. Transfemale patients may elect to undergo breast augmentation surgery using 
implants or lipofilling. They may also elect to have an orchiectomy and vaginoplasty (Coleman, 
et al, 2012).  
 
Hormonal therapy 
Hormone therapy can help to promote the outward or external appearance to be more in 
line with what that individual feels. It can take an average three to six months to see any physical 
effects from the hormones with maximum effects taking up to five years (Coleman, et al., 2012). 
Patients must meet the criteria for hormone therapy prior to initiation. This includes the 
diagnosis of persistent gender dysphoria, the capacity to make informed decisions and consent to 
treatment, and if significant medical or mental health concerns are present, they must be well-
controlled (Coleman, et al., 2012).  
The purpose of hormonal treatment for FTM is to reduce female secondary sex 
characteristics, including menses, and induce male secondary sex characteristics. It is important 
to discuss with the patient that complete elimination of the natal sex characteristics is rare 
(Steinle, 2011). Hormonal treatment for MTF is to reduce male secondary sex characteristics and 
induce female secondary sex characteristics. This is done using the lowest effective dose that 
will optimize desired effect and provide the lowest risk of side effects. Hormone therapy 
including desired effects, risks or potential risks, and dosing is noted in table 3. 
Hormone levels should be checked monthly until an appropriate dose is established. After 
this, monitoring is required every three to four months for the first year, completing a directed 
history and physical, ALT, fasting glucose and lipid panel, CBC, and trough hormone levels. 
After one year, if stable, monitoring can move to every six to twelve months (Steinle, 2011). 
Target for hormone therapy for FTM is to increase testosterone levels to that of a normal male 
(300-1000 ng/dl). Target for hormone therapy for MTF is to decrease testosterone levels to that 
of a normal female (30-100 ng/dl) without supra-physiological levels of estradiol (<200 pg/ml) 
by administering estrogen and an antiandrogen, such as spironolactone (Gardner & Safer, 2013). 
Screening is needed prior to the initiation of hormone treatment and this can be 
accomplished by a primary care provider who is knowledgeable about protocols (Steinle, 2011). 
First, a complete history and physical, including gynecological and psychological evaluations, 
needs to be completed. Family history, particularly pertaining to reproductive cancers, early 
atherosclerosis, hypertension, hyperlipidemia, and diabetes, needs to be ascertained. For women 
who chose to have top surgery (double mastectomy), it is important to do a chest wall exam and 
axillary lymph node exam if any breast tissue remain (Steinle, 2011). Lab tests that would be 
prudent include fasting lipid panel, fasting glucose or HgBA1c, pregnancy test if sexually active 
with natal man, liver and kidney functions, hormone levels (female—estradiol, testosterone, 
prolactin, luteinizing hormone), Pap smear/HPV, STD screening, and sleep apnea evaluation.  
  Contraindications to testosterone treatment includes pregnancy, unstable coronary artery 
disease, androgen-sensitive breast cancer, or active endometrial cancer. Possible 
contraindications include cardiovascular disease, hyperlipidemia with cardiac complications, 
cerebrovascular disease, thromboembolic disease, history of deep vein thrombosis, 
polycythemia, severe obstructive sleep apnea, and active substance abuse (Steinle, 2011). 
Contraindications to estrogen treatment include previous thrombotic events related to an 
underlying hypercoagulable condition, history of estrogen-sensitive neoplasm, and end-stage 
chronic liver disease (Coleman et al, 2012).   Risks involved with hormone therapy are described 
in table 3. 
 Responsibilities of hormone prescribing providers includes performing the initial 
evaluation as noted previously, discussing with the patient the risks and benefits of the hormone 
therapy including reproductive options, confirming the patient has the capacity to make informed 
decisions, provide ongoing monitoring, communicate regularly with the patient’s health care 
team as applicable, and if needed provide the patient with a written statement indicating that they 
are currently under medical supervision and treatment that includes hormone therapy, should the 
patient need this for legal authorities (Coleman, et al., 2012).  
Special considerations 
 There are special considerations that need to be made due to medication choice, delivery 
mode, and patient history. It is important to monitor patients every three months for the first year 
of hormone therapy once the dose is stabilized, then again every six to twelve months. These 
recommendations are summarized in table 4 to facilitate use in practice. 
 Cardiovascular. Blood pressure needs to be monitored as both estrogen and testosterone 
may increase blood pressure, especially in the presence of risk factors. Hormone therapy can also 
have an effect on the lipid panel (Coleman, et al, 2012).  
FTM 
 Testosterone may decrease the HDL and can have variable effects on the LDL and 
triglycerides (Holmes and Freeman, 2012). Administration by intramuscular injection may 
worsen this, so transdermal would be preferred. Patients with underlying risk factors such as 
PCOS and dyslipidemia are more likely to experience this. Testosterone can cause significant 
weight gain (more than 10%), particularly in the abdomen (Holmes and Freeman, 2012). 
 MTF 
 Estrogen can increase triglycerides, cardiovascular events, and the risk of pancreatitis. 
Different modes of administration will impact this risk, with transdermal decreasing the risk, 
thus a better choice for those with a pre-existing lipid disorder (Coleman et al, 2012). Estrogen 
can also increase the risk of cardiovascular events in patient over the age of 50 with underlying 
risk factors. Additional progestin use can increase this risk further (Coleman et al, 2012).  
 Hematopoesis and Liver. Both estrogen and testosterone can cause transient elevation in 
liver enzymes (Holmes and Freeman, 2012) but rarely hepatotoxicity (Coleman et al., 2012). 
FTM 
Testosterone therapy can cause erythrocytosis (hematocrit > 50%), though this is dose 
dependent with a higher risk occurring with injections (44%) and less with transdermal 
preparation (3-18%) (Coleman, et al., 2012). If FTM and taking spironolactone, it is important to 
monitor the potassium level to prevent hyperkalemia (Garner and Safer, 2013).  
MTF 
Monitoring for venous thromboembolism (VTE) should be done as the risk is increased 
in patients over the age of 40, smokers, sedentary and/or obese individuals, those with any 
underlying predisposition, and those using additional third generation progestins (Coleman et al., 
2012). This risk is decreased if using the transdermal preparation of estradiol, thus transdermal is 
recommended for patients that are a higher risk of VTE. Estrogen increases the risk of 
cholelithiasis and subsequent cholecystectomy (Coleman et al., 2012).  
Endocrine. It is important to monitor for diabetes in the setting of hormone therapy as 
both estrogen and testosterone can produce an increased risk for diabetes. 
MTF 
Estrogen increases the risk of hyperprolactinemia in the first year of treatment and high 
dose estrogen may promote clinical appearance of preexisting but clinically unapparent 
prolactinoma (Coleman et al., 2012). It is important to monitor the prolactin level regularly. 
Cancer.  
MTF  
An annual mammogram should be done in any patients age 50 or older who have 
undergone at least 5 years of hormone treatment. It should also be completed on anyone with a 
body mass index over 35, or one with known risk factors such as Klinefelter syndrome (Coleman 
et all., 2012), and anyone with a positive family history (Phillips et al., 2014). Prostate cancer 
screening should be conducted according to the guidelines if the prostate remains. (Coleman et 
al., 2012). 
FTM  
An annual mammogram should be completed if they have had a reduction mammoplasty, 
over 40 years of age at the time of surgery, or not had any top surgery (Coleman et al., 2012). 
They should have a yearly chest wall/axillary exam if they had a bilateral mastectomy (Phillips 
et al., 2014). Cervical cancer should be conducted according to guidelines if the cervix remains 
(Coleman et al., 2012).  
Psychological. Screening for mental health issues should occur with both MTF and FTM 
patients. Screening should include depression, suicide, Post Traumatic Stress Disorder (PTSD), 
and Eating disorders, anxiety (Coleman et al., 2012). Substance abuse screening should be 
completed, though the potential for abuse is less likely in patients undergoing hormone therapy 
as they are addressing the disconnect and not needing to self-medicate (Holmes and Freeman, 
2012). 
FTM 
Testosterone treatment may increase the risk of hypomania, mania, or psychotic 
symptoms in people who have a predisposition. This is a dose related response that typically 
occurs with supraphysiologic blood levels (Coleman et al., 2012).  
Musculoskeletal. Screening for osteoporosis should be done in both FTM and MTF 
patients. A bone mineral density or DEXA scan should be done prior to the initiation of 
testosterone therapy if the person is at risk for osteoporosis. Otherwise it is recommended to start 
DEXA scans at age 60 or earlier if hormone levels are consistently low (Gardner and Safer, 
2013).  
FTM  
Testosterone maintains or increases the bone mineral density prior to an oophorectomy 
and in the first three years of treatment. There will be an increased risk of bone mineral density 
loss after an oophorectomy if the testosterone treatment is interrupted or insufficient (Coleman et 
al., 2012).  
Skin, Hair, Nails.  
FTM 
Testosterone can contribute to acne and androgenic alopecia (Coleman et al., 2012). It is 
important to educate the patient regarding good skin care.  
Sexual. There is an increased risk of sexually transmitted diseases in the presence of high 
risk behaviors as with any individual (Redfern & Sinclair, 2014). Fertility is impaired with 
hormone therapy. Changes will occur in libido, with estrogen decreasing libido and testosterone 
increasing libido. Estrogen will decrease nocturnal erections, with a variable impact on sexually 
stimulated erections (Coleman et al., 2012).  
Lab Interpretation. Interpreting values that have different reference ranges for males 
and females can prove complicating for providers. Some tests have gender specific reference 
ranges. Liver enzymes, lipid profiles, and cardiac markers are reported based on the indicated 
sex of the patient. It is not clear when the patient is transgender (Roberts & Fantz, 2014). The NP 
may consult with a transgender specialist to determine which range to follow and when in that 
patient’s treatment course it should change.  
Summary 
There are many aspects of healthcare related to the transgender patient. There is a need 
for culturally sensitive and competent care. Unfortunately, there is a lack of education regarding 
care for the transgender patient in nursing and medical schools as well as a lack of resources 
available for the practicing provider, leaving the transgender person with great disparity 
regarding accessing quality care. There is new terminology and understanding of the transition 
process, including hormone therapy and surgery. The practitioner must understand where 
resources can be located as well as develop competence in ensuring thorough health care 
maintenance issues for patients undergoing hormone therapy. By gaining this knowledge, the NP 
can improve access to quality healthcare, improving outcomes through the provision of 
competent, compassionate, culturally sensitive care. The NP is well trained to provide advocacy, 
care coordination, and provision of healthcare. This will result in individualized quality patient 
centered care, which should lead to an optimum state of health.  
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Table 1: Resources regarding transgender care 
A Provider's Introduction to Substance Abuse 
Treatment for Lesbian, Gay, Bisexual, and 
Transgender Individuals (SAMHSA) 
http://store.samhsa.gov/product/A-Provider-s-
Introduction-to-Substance-Abuse-Treatment-for-
Lesbian-Gay-Bisexual-and-Transgender-
Individuals/SMA12-4104 
Lesbian, Gay, Bisexual, and Transgender 
Health 
http://www.cdc.gov/lgbthealth/transgender.htm 
Center of Excellence for Transgender Health http://transhealth.ucsf.edu/trans?page=home-00-00 
National LGBT Health Education Center http://www.lgbthealtheducation.org/training/learning-
modules/ 
Guidelines for care of Lesbian, Gay, Bisexual, 
and Transgender patients 
http://www.lgbthealtheducation.org/training/learning-
modules/ 
Advancing Effective Communication, Cultural 
Competence, and Patient- and Family-Centered 
Care for the Lesbian, Gay, Bisexual, and 
Transgender (LGBT) Community 
http://www.jointcommission.org/lgbt/ 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Definitions related to transgender 
Source: (Gay Alliance, 2013, American Psychiatric Association, 2013). 
 
 
 
 
Gender Dysphoria 
    
• marked incongruence between one’s experienced or expressed gender 
and their assigned gender 
• must be present for at least 6 months  
• must be manifested by a strong desire to be the other gender or some 
alternative gender that differs from their assigned gender.  
• must also be associated with significant distress or impairment 
regarding social, school, or other important areas of functioning 
Gender Range of characteristics of men and women/ masculinity and femininity 
assigned by society. 
Gender 
expression/Gender 
role 
Expression of masculinity or femininity by a person based on societal, 
cultural, and individual expectations.  
 
Gender identity A person’s sexual identity with male, female, neither, or both.  
 
Genderqueer A person who does not identify with either male or female. They may 
identify with both, neither, or somewhere in between.  
 
Transgender 
 
Umbrella term that includes anyone whose self-identity, behavior, or 
anatomy falls outside of societal norms and expectations 
Transsexual Person whose gender identity is not congruent with their biological sex. 
They may or may not pursue treatment to bring congruency to their 
gender identity. 
 
Transmale Individual who was born a female but identifies with male and MAY 
have used hormonal and/or surgical treatment to become a male. 
 
Transfemale:  
 
Individual who was born a male but identifies with female and MAY 
have used hormonal and/or surgical treatment to become a female. 
Two Spirit 
 
Native American term that refers to someone who identifies with both 
multiple genders. 
Cisgender The state of not being transgender; people who identify with the sex that 
they were assigned at birth 
 
Table 3: Hormone therapy--desired effects, risks, dosing  
Source: (Gardner & Safer, 2013, Coleman, et al., 2012) 
 
 
 
FTM 
• Voice 
deepening  
• Clitoral 
enlargement 
• Facial/Body 
hair growth 
• Menses 
cessation 
• Breast tissue 
atrophy 
• Body fat 
percentage 
decrease 
(compared to 
muscle mass) 
Increased Risk:  
Polycythemia 
Weight gain 
Acne 
Androgenic alopecia 
(balding) 
Sleep apnea 
Potential risk: 
Hyperlipidemia 
Potentiated psychiatric 
disorders (in presence of risk 
factors present) 
CVD (in presence of risk 
factors) 
HTN (in presence of risk 
factors) 
HTN (in presence of risk 
factors) 
Type 2 DM 
Elevated liver enzymes 
Oral Testosterone 
undecanoate 
(only available 
outside US) 
160-240 
mg/day 
Parenteral Testosterone 
enanthate or 
cypionate 
50-200 
mg/week or 
100-200 
mg/2 weeks 
 Testosterone 
undecanoate 
(only available 
outside US) 
1000 mg/12 
weeks 
Transdermal Testosterone 
1% gel 
2.5-10g/day 
 Testosterone 
patch 
2.5-7.5 
mg/day 
   
MTF 
• Breast tissue 
growth 
• Erectile 
function 
decrease 
• Testicular size 
decrease 
• Body fat 
percentage 
increase 
(compared to 
muscle mass) 
Increased Risk:  
Venous thromboembolic 
disease 
Gallstones 
Elevated liver enzymes 
Weight gain 
Hypertriglyceridemia 
CVD (in presence of risk 
factors) 
Potential risk: 
HTN 
Hyperprolactinemia or 
prolactinoma 
Type 2 DM 
Anti-androgen Spironolactone 100-
200mg/day 
(up to 400 
mg) 
 Cyproterone 
acetate (only 
available 
outside US) 
50-100 
mg/day 
 GnRH agonists 3.75 mg 
subcutaneous 
monthly 
Oral Estrogen Oral 
conjugated 
estrogens 
2.5-7.5 
mg/day 
 Oral 17-beta 
estradiol 
2-6 mg/day 
Parenteral Estradiol 
valerate or 
cypionate 
5-20 mg 
IM/2 weeks 
or 2-10 mg 
IM/week 
Transdermal Estradiol patch 0.1-0.4 
mg/2X week 
 Table 4 Monitoring recommendations 
MTF FTM 
Issue Effect Recommendation Issue Effect Recommendation 
BP Increase BP Monitor BP  BP May increase 
BP, especially 
in setting of 
risk factors 
Monitor BP 
Lipids Increase 
Triglycerides, 
increase risk 
pancreatitis 
Use transdermal to 
lessen effect 
particularly if high 
risk; monitor lipid 
panel every 3-4 
months 1st yr, then 
every 6-12 mos 
Lipids Decrease HDL, 
variable effects 
LDL, 
Triglycerides 
IM may worsen; use 
transdermal to lessen 
effect, particularly if 
high risk (PCOS, 
dyslipidemia) 
monitor lipid panel 
every 3-4 months 1st 
yr, then every 6-12 
mos 
CV 
Events 
Increased risk 
CV events in 
pts >50 with 
underlying 
risk factors, 
particularly 
with 
additional 
progestin 
Monitor for risk 
factors, reduce as 
is feasible 
Weight 
gain 
>10% weight 
gain, mostly in 
abdomen 
Monitor weight gain; 
encourage exercise 
Potassium Increased risk 
if taking 
spironolacton
e 
Monitor potassium 
level every 3-4 
months 1st yr, then 
every 6-12 mos 
Erythrocyt
osis (Hct 
>50%) 
Dose and mode 
dependent 
(44% IM, 18% 
transdermal) 
Use Transdermal to 
decrease risk 
Monitor CBC every 3-
4 months 1st yr, then 
every 6-12 mos 
VTE Risk 
increased if 
>40, smokers, 
sedentary, 
obese, 
underlying 
thrombophilic 
disorder, 
additional 3rd 
generation 
progestin use 
Monitor for VTE; 
Use transdermal if 
high risk 
Skin, Hair, 
Nails 
Acne, 
androgenic 
alopecia 
Patient counseling 
regarding skin care 
Liver Transient 
elevation 
enzymes; 
increases risk 
cholelithiasis 
and 
cholecystecto
my 
Monitor ALT 
every 3-4 mo 1st 
yr, then every 6-12 
mos 
Liver  Transient 
elevation 
enzymes 
Monitor ALT every 3-
4 mo 1st yr, then every 
6-12 mos 
Endo-
crine 
Increase risk 
of Type II 
DM 
Fasting glucose 
every 3-4 mos 1st 
yr, then every 6-12 
mos 
Endocrine Decrease 
insulin 
sensitivity 
Fasting glucose every 
3-4 mos 1st yr, then 
every 6-12 mos 
Hormone 
levels 
Increase risk 
of 
hyperprolacti
nemia in 1st yr 
tx; high dose 
may promote 
clinical 
appearance 
preexisting 
but clinically 
unapparent 
Monitor Prolactin 
level, trough 
hormone levels 
every 3-4 mos 1st 
yr, then every 6-12 
mos 
 Hormone 
levels 
Monitor trough 
hormone levels 
monthly until optimal 
dose attained, then 
every 3-4 months 1st 
yr, then every 6-12 
mos 
 Breast 
Cancer 
mammograph
y 
Annual: >50 
with > 5 yrs tx; 
BMI >35; + family 
hx; known risk 
factors (Klinefelter 
syndrome) 
Breast 
cancer 
Mammography 
 
 
 
 
 
Annual: reduction 
mammoplasty or no 
surgery, preop > 40 
age 
 
Yearly chest wall 
exam if bilat 
mastectomy 
Prostate 
Cancer 
Prostate exam According to natal 
guidelines if 
prostate remains 
Cervical 
Cancer 
Pap smear According to natal 
guidelines if cervix 
remains 
Psych Screening for 
depression, 
suicide, 
PTSD, eating 
disorders, 
anxiety, 
substance 
abuse 
All patients each 
appointment 
Psych Screening for 
depression, 
suicide, PTSD, 
eating 
disorders, 
anxiety, 
substance 
abuse 
May increase 
risk 
hypomanic, 
manic, or 
All patients each 
appointment 
psychotic sx if 
predisposition, 
though dose 
dependent or if 
supra-
physiological 
hormone levels 
Osteo-
porosis 
DEXA Scan Prior to initiation 
tx if risk factors; 
Age 60 or earlier if 
hormone levels 
consistently low 
Osteo-
porosis 
DEXA Scan Prior to initiation tx if 
risk factors; Age 60 or 
earlier if hormone 
levels consistently low 
If oophorectomy, 
increased risk if tx 
interrupted or 
insufficient 
STD Increased risk 
due to high 
risk behaviors 
Screen for STD as 
warranted 
STD Increased risk 
due to high 
risk behaviors 
Screen for STD as 
warranted 
Sexual 
Health 
Impaired 
fertility 
Decreased 
Libido 
Decrease 
nocturnal 
erections, 
variable effect 
on sexually 
stimulated 
erections 
Use lowest 
possible dose for 
optimal effect 
Sexual 
Health 
Impaired 
fertility 
Increased 
Libido 
Use lowest possible 
dose for optimal effect 
Source: (Coleman et al, 2012, Holmes and Freeman, 2012, Garner and Safer, 2013, Steinle, 2011, 
Phillips, et.al, 2014, Redfern & Sinclair, 2014) 
 
